Head And Neck Cancer (HNC) Market Is Set To Expand Significantly In Terms Of Revenue And CAGR By 2030
The head and neck cancer (hnc) market size is expected to see strong growth in the next few years. It will grow to $3.12 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing investments in precision oncology research, rising demand for minimally invasive treatments, expansion of immunotherapy pipelines, growing use of AI-assisted diagnostics, increasing focus on personalized cancer care. Major trends in the forecast period include increasing adoption of targeted and immunotherapy treatments, rising use of advanced diagnostic imaging techniques, growing focus on early cancer detection, expansion of multimodal treatment approaches, enhanced integration of precision oncology.
Claim Your Free Report Sample Today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20825&type=smp
What Are The Main Market Drivers Shaping The Progression Of The Head And Neck Cancer (HNC) Market?
The increasing incidences of cigarette smoking is expected to propel the growth of the head and neck cancer (HNC) market going forward. Cigarette smoking is the act of inhaling and exhaling smoke from burning tobacco contained in cigarettes, often associated with health risks and addiction. The increasing cigarette smoking incidence is often driven by factors such as stress, social influences, aggressive marketing, and accessibility of tobacco products. Head and neck cancer drugs help mitigate the harmful effects of cigarette smoking by targeting smoking-induced molecular alterations and treating cancers linked to tobacco use, while also emphasizing the need to reduce exposure to smoking-related carcinogens for better treatment outcomes. For instance, in October 2024, according to the European Respiratory Society (ERS), a Switzerland-based non-profit organization, a study covering smoking trends among young people revealed a significant rise in smoking rates, with 22.5% of respondents smoking in 2022 compared to 40.1% in 2024. Therefore, the increased incidence of cigarette smoking is driving the growth of the head and neck cancer (HNC) market.
What Leading Segment Types Are Used To Analyze The Head And Neck Cancer (HNC) Market?
The head and neck cancer (hnc) market covered in this report is segmented –
1) By Type: Laryngeal Cancer, Pharyngeal Cancer, Salivary Gland Cancer, Lip And Oral Cavity Cancer, Nasopharyngeal Cancer
2) By Treatment: Chemotherapy, Surgery, Radiation Therapy, Targeted Therapy, Other Treatments
3) By Diagnosis: Bioscopy Screening Tests, Dental Diagnosis, Imaging, Endoscopy
4) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies
5) By End User: Hospital, Specialty Clinics
Subsegments:
1) By Laryngeal Cancer: Supraglottic Laryngeal Cancer, Glottic Laryngeal Cancer, Subglottic Laryngeal Cancer
2) By Pharyngeal Cancer: Oropharyngeal Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer
3) By Salivary Gland Cancer: Parotid Gland Cancer, Sublingual Gland Cancer, Submandibular Gland Cancer, Minor Salivary Gland Cancer
4) By Lip And Oral Cavity Cancer: Lip Cancer, Buccal Mucosa Cancer, Tongue Cancer, Gingival Cancer, Palate Cancer
5) By Nasopharyngeal Cancer: Early-Stage Nasopharyngeal Cancer, Advanced-Stage Nasopharyngeal Cancer
Which Trends Are Currently Influencing The Direction Of The Head And Neck Cancer (HNC) Market?
Major companies operating in the head and neck cancer (HNC) market are focusing on developing innovative formulations such as immune oncology drugs, to enhance treatment efficacy, improve patient survival rates, and address unmet medical needs in managing complex and advanced-stage cancers. Immuno-oncology drugs refer to treatments that harness the body's immune system to recognize and fight cancer cells. These therapies include checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines. For instance, in November 2024, Dr. Reddy's Laboratories, an India-based pharmaceutical company, launched toripalimab, an immune oncology drug for adults with a rare form of head and neck cancer that originates in the nasopharynx, the upper part of the throat. This drug is designed for treating recurrent or metastatic nasopharyngeal carcinoma. It will be marketed under the name Zytorvi. The drug has demonstrated a 48% reduction in the risk of progression or death when used in combination with standard chemotherapy (gemcitabine and cisplatin).
Who Are The Core Market Contributors Recognized Within The Head And Neck Cancer (HNC) Market Ecosystem?
Major companies operating in the head and neck cancer (hnc) market are Pfizer Inc., Siemens Healthcare Private Limited, F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Healthcare AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Koninklijke Philips N.V., Boehringer Ingelheim, Fresenius Kabi AG, Incyte Corporation, Exelixis Inc., Astellas Pharma Inc., Rakuten Medical Inc., Merus N.V.
Get Your In-Depth Head And Neck Cancer (HNC) Market Report Now:
https://www.thebusinessresearchcompany.com/report/head-and-neck-cancer-hnc-global-market-report
Which Locations Are Showing Rapid Adoption And Strong Growth Indicators In The Head And Neck Cancer (HNC) Market?
North America was the largest region in the head and neck cancer (HNC) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the head and neck cancer (hnc) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
#Contact Us:#
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
#Follow Us On:#
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment